{"title":"重组ACE2-Ig融合蛋白中和SARS-CoV-2","authors":"Jin-Woo Song, Young‐Sang Koh","doi":"10.4167/jbv.2022.52.1.039","DOIUrl":null,"url":null,"abstract":"A novel coronavirus (SARS-CoV-2) is the causative agent for the COVID-19 pandemic, and needs for effective antiviral drugs have been demanded. Angiotensin-converting enzyme 2 (ACE2) has been shown to be a cellular receptor for SARS-CoV and SARS-CoV-2. For the therapeutic validation of ACE2, a recombinant protein consisting of the ACE2 extracellular domain fused to the IgG1 Fc domain (ACE2-Ig) was generated. ACE2-Ig exhibits proper pharmacological properties and binds with a high affinity to SARS-CoV and SARS-CoV-2 receptor-binding domain. Further, it neutralizes virus with SARS-CoV and SARS-CoV-2 spike proteins. Taken overall, these data suggest that ACE2-Ig has substantial anti-SARS-CoV-2 properties and warrant further study concerning its potential applications for the treatment of SARS-CoV-2. © 2022 Journal of Bacteriology and Virology.","PeriodicalId":39739,"journal":{"name":"Journal of Bacteriology and Virology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recombinant ACE2-Ig Fusion Protein Neutralizes SARS-CoV-2\",\"authors\":\"Jin-Woo Song, Young‐Sang Koh\",\"doi\":\"10.4167/jbv.2022.52.1.039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A novel coronavirus (SARS-CoV-2) is the causative agent for the COVID-19 pandemic, and needs for effective antiviral drugs have been demanded. Angiotensin-converting enzyme 2 (ACE2) has been shown to be a cellular receptor for SARS-CoV and SARS-CoV-2. For the therapeutic validation of ACE2, a recombinant protein consisting of the ACE2 extracellular domain fused to the IgG1 Fc domain (ACE2-Ig) was generated. ACE2-Ig exhibits proper pharmacological properties and binds with a high affinity to SARS-CoV and SARS-CoV-2 receptor-binding domain. Further, it neutralizes virus with SARS-CoV and SARS-CoV-2 spike proteins. Taken overall, these data suggest that ACE2-Ig has substantial anti-SARS-CoV-2 properties and warrant further study concerning its potential applications for the treatment of SARS-CoV-2. © 2022 Journal of Bacteriology and Virology.\",\"PeriodicalId\":39739,\"journal\":{\"name\":\"Journal of Bacteriology and Virology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bacteriology and Virology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4167/jbv.2022.52.1.039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bacteriology and Virology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4167/jbv.2022.52.1.039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
引用次数: 0
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
